Ribavirin enhances the action of interferon-α against hepatitis C virus by promoting the p53 activity through the ERK1/2 pathway.
<h4>Background/aims</h4>Ribavirin significantly enhances the antiviral response of interferon-α (IFN-α) against Hepatitis C virus (HCV), but the underlying mechanisms remain poorly understood. Recently, p53 has been identified as an important factor involving the suppression of HCV repli...
Guardado en:
Autores principales: | Wei-Liang Liu, Hung-Chih Yang, Wen-Cheng Su, Chih-Chiang Wang, Hui-Ling Chen, Hurng-Yi Wang, Wen-Hung Huang, Ding-Shinn Chen, Ming-Yang Lai |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2012
|
Materias: | |
Acceso en línea: | https://doaj.org/article/294a1618e42a4fe6a18367950b085b15 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Role of microRNA modulation in the interferon-α/ribavirin suppression of HIV-1 in vivo.
por: Mohamed Abdel-Mohsen, et al.
Publicado: (2014) -
Efficacy and safety of pegylated interferon plus ribavirin therapy for chronic hepatitis C genotype 6: a meta-analysis.
por: Xiwei Wang, et al.
Publicado: (2014) -
Aspartate aminotransferase to platelet ratio index and sustained virologic response are associated with progression from hepatitis C associated liver cirrhosis to hepatocellular carcinoma after treatment with pegylated interferon plus ribavirin
por: Ng KJ, et al.
Publicado: (2016) -
Predictive factors for sustained virological response after treatment with pegylated interferon α-2a and ribavirin in patients infected with HCV genotypes 2 and 3.
por: Claus Niederau, et al.
Publicado: (2014) -
IL28B SNP rs8099917 is strongly associated with pegylated interferon-α and ribavirin therapy treatment failure in HCV/HIV-1 coinfected patients.
por: Ester Aparicio, et al.
Publicado: (2010)